| 55.26 26.9 (94.85%) | 10-24 14:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 67.45 |
1-year : | 78.79 |
| Resists | First : | 57.75 |
Second : | 67.45 |
| Pivot price | 35.94 |
|||
| Supports | First : | 38.25 |
Second : | 26.2 |
| MAs | MA(5) : | 38.14 |
MA(20) : | 35.49 |
| MA(100) : | 24.79 |
MA(250) : | 18.12 |
|
| MACD | MACD : | 2.7 |
Signal : | 2 |
| %K %D | K(14,3) : | 35.1 |
D(3) : | 41.7  |
| RSI | RSI(14): 74.7 |
|||
| 52-week | High : | 57.75 | Low : | 10.8 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ INBX ] has closed above the upper band by 34.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 261.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 36.39 - 36.61 | 36.61 - 36.77 |
| Low: | 27.75 - 27.98 | 27.98 - 28.15 |
| Close: | 28.06 - 28.4 | 28.4 - 28.65 |
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Fri, 24 Oct 2025
Ford, Inhibrx Biosciences, Comfort Systems, Western Union And Other Big Stocks Moving Higher On Friday - Benzinga
Fri, 24 Oct 2025
Why Is Inhibrx Stock Rising? - StocksToTrade
Fri, 24 Oct 2025
INBX Stock: Is Success on the Horizon? - timothysykes.com
Fri, 24 Oct 2025
Why Is Inhibrx Biosciences (INBX) Stock Surging in Premarket Today? - Tokenist
Fri, 24 Oct 2025
Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News - ts2.tech
Fri, 24 Oct 2025
Why Are Inhibrx Biosciences Shares Soaring 76% After Hours? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -43 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.449e+007 (%) |
| Held by Institutions | 8.16e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7177e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -16.57 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 106.8 % |
| Return on Equity (ttm) | -26.3 % |
| Qtrly Rev. Growth | 1.4e+006 % |
| Gross Profit (p.s.) | 172.36 |
| Sales Per Share | -165.04 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -9.617e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -3.33 |
| Price to Sales | -0.34 |
| Price to Cash Flow | 0 |
| Dividend | 524530 |
| Forward Dividend | 792240 |
| Dividend Yield | 951960% |
| Dividend Pay Date | 2025-01-19 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|